Pharma companies directory 2026

    Pharmaceutical Companies in Vietnam

    Vietnam has become one of Asia’s fastest-expanding medicine markets, with the Drug Administration of Vietnam tracking 6–8% annual growth and independent estimates placing 2024–2025 sales near eight billion dollars as the country moves toward an eight-billion-dollar DAV target for 2026.

    Domestic plants now cover roughly three fifths of unit demand and a little under half of value, so imported originators and high-tech injectables still set the price ceiling in hospitals while listed Mekong Delta and Hanoi manufacturers fight for the reimbursed oral-solid majority. Circulation licences sit with the Drug Administration of Vietnam under the Ministry of Health; without a DAV số đăng ký a pack cannot legally enter a hospital bid or a retail pharmacy. Payment for most inpatient and many outpatient scripts then runs through Vietnam Social Security, whose provincial bidding rounds convert the national essential-medicine list into awarded volumes for DHG, Traphaco, Imexpharm, Pymepharco and a long tail of smaller HOSE names. Parallel to that public spine, Sanofi’s historic Ho Chi Minh City affiliate, Stada’s Stellapharm campus in Binh Duong, and the two ASEAN logistics majors DKSH and Zuellig move specialty and consumer lines into private hospitals and the Long Chau, Pharmacity and An Khang chains. Sixty-seven firms shipped $312 million of finished medicines and ingredients in 2025, fourth in Southeast Asia, with foreign-invested plants contributing about three quarters of that export value. BioNixus keeps the roster below because these are the licence holders, payers, plants and trade houses that recur when a client asks who actually wins a class in Hanoi, Ho Chi Minh City, Can Tho or Da Nang.

    Updated September 2026 · Drug Administration of Vietnam (DAV) — registered drug products and licensed pharmaceutical establishments as of September 2026 · 20 named accounts

    Request a proposal for VietnamBrowse the 20 companies

    $7.9–8.6bn

    Vietnamese pharmaceutical market value, 2024–2025 (Fortune / IMARC / DAV trajectory)

    ~60%

    Share of domestic unit demand met by Vietnamese plants (about 46% by value)

    $312m

    Finished-medicine and ingredient exports in 2025; 67 exporting companies

    6–8%

    DAV-reported annual market growth rate

    Named accounts

    Top pharmaceutical companies in Vietnam

    Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against Drug Administration of Vietnam (DAV) — registered drug products and licensed pharmaceutical establishments (as of 2026-09-04).
    #CompanyHQ
    01Drug Administration of Vietnam (DAV)Hanoi
    02Vietnam Social Security (VSS / BHXH)Hanoi
    03DHG PharmaceuticalCan Tho
    04TraphacoHanoi
    05ImexpharmCao Lanh
    06PymepharcoTuy Hoa
    07Domesco Medical Import ExportCao Lanh
    08Mekophar Chemical PharmaceuticalHo Chi Minh City
    09OPC PharmaceuticalHo Chi Minh City
    10Sanofi VietnamHo Chi Minh City
    11Stellapharm (Stada Vietnam)Binh Duong
    12GSK VietnamHo Chi Minh City
    13DKSH VietnamHo Chi Minh City
    14Zuellig Pharma VietnamHo Chi Minh City
    15Hoang Duc PharmaceuticalHo Chi Minh City
    16TV.PharmTra Vinh
    17Ha Tay Pharmaceutical (HATAPHAR)Hanoi
    18Pfizer VietnamHo Chi Minh City
    19Roche VietnamHo Chi Minh City
    20AstraZeneca VietnamHo Chi Minh City

    Primary research

    These are the pharmaceutical companies accounts we study in Vietnam

    Need account-level or SKU-level data for a brand in Vietnam? BioNixus runs primary fieldwork — brand vs competitors, including the channels a dashboard averages away. Proposal ready within 48 hours of a brief.

    Planning research in Vietnam?

    Primary research, market access & HEOR. Proposals within 48 hours.

    BioNixus research services

    How the market is structured

    How a medicine is licensed, bid and dispensed in Vietnam

    A finished pack reaches a Vietnamese patient only after the Drug Administration of Vietnam issues a marketing authorisation and, for a foreign plant, accepts a GMP dossier that is increasingly aligned with PIC/S expectations. The holder of that licence must be a Vietnamese legal entity: a domestic manufacturer, a 100% foreign-owned affiliate such as Sanofi Vietnam, or an importer such as Hoang Duc that registers and then appoints a logistics partner. Once the số đăng ký is live, hospital volume is decided in provincial and central bidding under the Pharmacy Law and the Ministry of Health’s tender circulars. Vietnam Social Security reimburses the winning SKU at the bid price for members of the compulsory social-health-insurance scheme, which now covers the large majority of the population, so a lost VSS lot in Hanoi or Ho Chi Minh City can erase a year’s forecast for an oral antibiotic or a statin. Private hospitals and the fast-growing pharmacy chains buy outside those lots, paying a premium for originator brands, consumer-health SKUs and cold-chain specialty products that DKSH and Zuellig warehouse in temperature-mapped depots. Retail still includes tens of thousands of independent nha thuoc, which listed domestic houses reach with their own medical representatives and van fleets. Local-content and “Make in Vietnam” language in recent industrial strategy documents is nudging multinationals toward toll or equity partnerships at plants that already hold EU or PIC/S GMP, which is why Taisho’s control of DHG, Adamed’s purchase of Pymepharco and Stada’s Binh Duong campus matter as much as any import licence. Pricing of reimbursed molecules is referenced to winning bid history, so a new generic that undercuts the last award can reset the class overnight.

    Local

    HOSE-listed Mekong and Hanoi manufacturers that win the bulk of VSS oral-solid lots and still own the pharmacy brands Vietnamese shoppers ask for by name.

    • DHG Pharmaceutical
    • Traphaco
    • Imexpharm
    • Domesco Medical Import Export
    • Mekophar Chemical Pharmaceutical
    • OPC Pharmaceutical
    • TV.Pharm
    • Ha Tay Pharmaceutical (HATAPHAR)

    Multinational

    Innovator and European-generic affiliates with Vietnamese plants or commercial offices, concentrated in vaccines, diabetes, respiratory care and export-grade generics.

    • Sanofi Vietnam
    • Stellapharm (Stada Vietnam)
    • GSK Vietnam
    • Pfizer Vietnam
    • Roche Vietnam
    • AstraZeneca Vietnam

    Regional

    Northeast Asian and Central European groups that bought controlling stakes in Vietnamese plants, using those sites as both a domestic tender vehicle and a regional hub.

    • Pymepharco

    Distributors & importers

    DAV as licence issuer, Vietnam Social Security as the reimbursing bidder, and the importer-plus-ASEAN-distributor layer that moves foreign packs into hospitals and chains.

    • Drug Administration of Vietnam (DAV)
    • Vietnam Social Security (VSS / BHXH)
    • DKSH Vietnam
    • Zuellig Pharma Vietnam
    • Hoang Duc Pharmaceutical

    What is moving

    What is moving the pharmaceutical market in Vietnam

    Social-insurance bidding as the volume switch

    Coverage expansion under Vietnam Social Security turns a won provincial lot into guaranteed hospital throughput, which is why domestic generics houses spend more time on bid strategy than on consumer advertising for reimbursed classes.

    Foreign equity in Mekong and Binh Duong plants

    Taisho at DHG, Adamed at Pymepharco and Stada at Stellapharm are upgrading PIC/S capacity that can serve both VSS tenders and export dossiers, changing who captures the next wave of toll-manufacturing mandates.

    Pharmacy-chain consolidation in the two metros

    Long Chau, Pharmacity and An Khang are centralising OTC and chronic-repeat purchasing in Hanoi and Ho Chi Minh City, so consumer-health and supplement launches now need chain listing as well as independent nha thuoc coverage.

    Export book growing from a low base

    Sixty-seven exporters shipped $312 million in 2025, and foreign-invested plants took most of that value, giving EU-GMP Vietnamese sites a second demand engine when domestic bid prices compress.

    BioNixus fieldwork

    How BioNixus studies pharmaceutical companies in Vietnam

    The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in Vietnam:
    • VSS lot reconstruction by molecule across Hanoi, Ho Chi Minh City, Da Nang and Can Tho awards, used to size public volume before a generic or biosimilar registration is filed.
    • Pharmacy purchase audits in Long Chau, Pharmacity and independent nha thuoc for hepatology, cardiometabolic and cough-cold baskets, reconciled against distributor invoices.
    • Prescriber conversations with endocrinologists and infectious-disease physicians in private hospitals on originator versus winning-bid generic choice when the patient pays out of pocket.
    • Due-diligence interviews with quality heads at DHG, Imexpharm, Pymepharco and Stellapharm on PIC/S status, spare capacity and willingness to take multinational toll contracts.

    Questions

    Frequently Asked Questions

    Who are the leading medicine manufacturers inside Vietnam?

    Among listed domestic houses, DHG in Can Tho, Traphaco in Hanoi, Imexpharm and Domesco in Dong Thap, plus Pymepharco in Phu Yen, appear most often in VSS award files and pharmacy audits. Sanofi Vietnam and Stellapharm are the foreign plants that brand teams treat as the other two poles of the market.

    What does the Drug Administration of Vietnam actually decide?

    DAV issues and withdraws circulation licences, inspects plants, clears imports, polices advertising and sits on the legal framework for hospital bidding. A molecule without a DAV số đăng ký cannot be reimbursed by Vietnam Social Security or sold in a licensed pharmacy.

    How do hospital tenders work under social insurance?

    Provincial and central hospitals run competitive bids against the essential-medicine list; Vietnam Social Security then pays the winning supplier at the awarded price for insured patients. Lowest technically compliant bids usually take the lot, which is why unbranded and lightly branded domestic generics dominate public volume.

    Can a foreign company sell without a Vietnamese plant?

    Yes, if a Vietnamese legal entity holds the DAV licence and a licensed importer or distributor handles GDP logistics. Many originators still appoint Hoang Duc, DKSH or Zuellig rather than build a factory, though industrial-policy language is making toll deals at PIC/S sites more attractive.

    What fieldwork does BioNixus run on Vietnamese pharmaceutical companies?

    Panels with hospital pharmacists and provincial bid officers in Hanoi, Ho Chi Minh City, Can Tho and Da Nang; purchase-record reads in chain and independent pharmacies for cardiometabolic and antibiotic baskets; reconstruction of VSS award histories by molecule; and plant-quality interviews at Mekong and Binh Duong sites that foreign principals are considering for toll work.

    Should readers treat this Vietnamese table as a league list?

    Sequence here follows role — regulator, payer, plants, affiliates, trade — not last year’s revenue. Names were chosen because they keep appearing in BioNixus Vietnam projects and on DAV and HOSE records, not because a rank was calculated.

    Sources

    Data sources & methodology

    This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in Vietnam. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

    Primary register: Drug Administration of Vietnam (DAV) — registered drug products and licensed pharmaceutical establishments, consulted 2026-09-04. Company classification (Local / MNC / Regional / distributors & importers) reflects ownership and role in Vietnam, not size.

    • Drug Administration of Vietnam statements on market growth, local production share and 2025 export value ($312 million; 67 exporters)
    • HOSE annual reports and disclosures for DHG Pharmaceutical, Traphaco, Imexpharm, Domesco, Mekophar, OPC and TV.Pharm, 2024–2025
    • Fortune Business Insights and IMARC Vietnam pharmaceuticals market estimates, 2024–2025; Ministry of Health tender and Pharmacy Law guidance
    • BioNixus Vietnam hospital-pharmacist, bid-officer and pharmacy fieldwork, 2023–2026

    BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

    48-hour proposal

    Need brand and competitor data in Vietnam?

    Physician, pharmacist and payer fieldwork on the accounts above — prescription share, formulary position and tender exposure. Proposal within 48 hours.

    Planning research in Vietnam?

    Primary research, market access & HEOR. Proposals within 48 hours.